BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21720382)

  • 1. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.
    Halldórsdóttir AM; Lundin A; Murray F; Mansouri L; Knuutila S; Sundström C; Laurell A; Ehrencrona H; Sander B; Rosenquist R
    Leukemia; 2011 Dec; 25(12):1904-8. PubMed ID: 21720382
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutation and survival in chronic lymphocytic leukemia.
    Zenz T; Eichhorst B; Busch R; Denzel T; Häbe S; Winkler D; Bühler A; Edelmann J; Bergmann M; Hopfinger G; Hensel M; Hallek M; Döhner H; Stilgenbauer S
    J Clin Oncol; 2010 Oct; 28(29):4473-9. PubMed ID: 20697090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma.
    Stokke T; DeAngelis P; Smedshammer L; Galteland E; Steen HB; Smeland EB; Delabie J; Holte H
    Br J Cancer; 2001 Dec; 85(12):1900-13. PubMed ID: 11747333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia.
    Seifert H; Mohr B; Thiede C; Oelschlägel U; Schäkel U; Illmer T; Soucek S; Ehninger G; Schaich M;
    Leukemia; 2009 Apr; 23(4):656-63. PubMed ID: 19151774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma.
    Stöcklein H; Smardova J; Macak J; Katzenberger T; Höller S; Wessendorf S; Hutter G; Dreyling M; Haralambieva E; Mäder U; Müller-Hermelink HK; Rosenwald A; Ott G; Kalla J
    Oncogene; 2008 Apr; 27(18):2613-25. PubMed ID: 17982487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine.
    Van Den Neste E; Robin V; Francart J; Hagemeijer A; Stul M; Vandenberghe P; Delannoy A; Sonet A; Deneys V; Costantini S; Ferrant A; Robert A; Michaux L
    Leukemia; 2007 Aug; 21(8):1715-22. PubMed ID: 17541398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH.
    Parry-Jones N; Matutes E; Morilla R; Brito-Babapulle V; Wotherspoon A; Swansbury GJ; Catovsky D
    Br J Haematol; 2007 Apr; 137(2):117-24. PubMed ID: 17391491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical aberrations of chromosome 17 and TP53 in brain metastases derived from breast cancer.
    Vasconcelos DS; da Silva FP; Quintana LG; Anselmo NP; Othman MA; Liehr T; de Oliveira EH
    Genet Mol Res; 2013 Jan; 12(3):2594-600. PubMed ID: 23315874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
    Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
    [No Abstract]   [Full Text] [Related]  

  • 13. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas.
    Wagata T; Shibagaki I; Imamura M; Shimada Y; Toguchida J; Yandell DW; Ikenaga M; Tobe T; Ishizaki K
    Cancer Res; 1993 Feb; 53(4):846-50. PubMed ID: 8094033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
    Obr A; Klener P; Furst T; Kriegova E; Zemanova Z; Urbankova H; Jirkuvova A; Petrackova A; Malarikova D; Forsterova K; Cudova B; Sedlarikova L; Berkova A; Kasalova N; Papajik T; Trneny M
    Br J Haematol; 2020 Dec; 191(5):e103-e106. PubMed ID: 32862455
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
    Espinet B; Salaverria I; Beà S; Ruiz-Xivillé N; Balagué O; Salido M; Costa D; Carreras J; Rodríguez-Vicente AE; Luís García J; Hernández-Rivas JM; Calasanz MJ; Siebert R; Ferrer A; Salar A; Carrió A; Polo N; García-Marco JA; Domingo A; González-Barca E; Romagosa V; Marugán I; López-Guillermo A; Millá F; Luís Mate J; Luño E; Sanzo C; Collado R; Oliver I; Monzó S; Palacín A; González T; Sant F; Salinas R; Ardanaz MT; Font L; Escoda L; Florensa L; Serrano S; Campo E; Solé F
    Genes Chromosomes Cancer; 2010 May; 49(5):439-51. PubMed ID: 20143418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytogenetic study of mantle cell lymphoma].
    Wang DM; Fan L; Fang C; Zhu DX; Dong H; Yang H; Qiu HR; Hong M; Qiao C; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):283-6. PubMed ID: 21644224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the TP53 gene in human gliomas.
    Rasheed BK; McLendon RE; Herndon JE; Friedman HS; Friedman AH; Bigner DD; Bigner SH
    Cancer Res; 1994 Mar; 54(5):1324-30. PubMed ID: 8118823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations.
    Sander S; Bullinger L; Leupolt E; Benner A; Kienle D; Katzenberger T; Kalla J; Ott G; Müller-Hermelink HK; Barth TF; Möller P; Lichter P; Döhner H; Stilgenbauer S
    Haematologica; 2008 May; 93(5):680-7. PubMed ID: 18367489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.